Exicure (XCUR) Net Cash Flow Growth (1y) (2017 - 2026)
Exicure (XCUR) Net Cash Flow Growth (1y) (2017 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
719,706.53 Bn |
719,706.50 Bn |
- |
- |
| 2 |
Belite Bio |
55,800.00 Bn |
55,800.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
18,182.30 Bn |
18,182.29 Bn |
- |
198.34% |
| 4 |
Legend Biotech |
3,154.00 Bn |
3,153.71 Bn |
242.10 Mn |
467.41% |
| 5 |
Akari Therapeutics |
1,844.30 Bn |
1,844.29 Bn |
- |
-14,223.53% |
| 6 |
Evaxion A |
1,567.96 Bn |
1,567.94 Bn |
- |
- |
| 7 |
Psyence Biomedical |
251.43 Bn |
251.42 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
112.56 Bn |
105.31 Bn |
2.59 Bn |
453.08% |
| 9 |
Abivax |
94.37 Bn |
94.37 Bn |
- |
- |
| 10 |
Exicure |
19.38 Mn |
16.77 Mn |
- |
45.31% |
| Date | Value |
|---|
| Mar 31, 2026 |
45.31% |
| Dec 31, 2025 |
-105.99% |
| Sep 30, 2025 |
-661.69% |
| Jun 30, 2025 |
-1,443.37% |
| Mar 31, 2025 |
-364.00% |
| Dec 31, 2024 |
11,002.83% |
| Sep 30, 2024 |
68.22% |
| Jun 30, 2024 |
97.82% |
| Mar 31, 2024 |
-132.54% |
| Dec 31, 2023 |
98.50% |
| Sep 30, 2023 |
74.55% |
| Jun 30, 2023 |
-183.25% |
| Mar 31, 2023 |
107.37% |
| Dec 31, 2022 |
23.50% |
| Sep 30, 2022 |
-159.71% |
| Jun 30, 2022 |
-132.47% |
| Mar 31, 2022 |
-1,913.73% |
| Dec 31, 2021 |
-612.53% |
| Sep 30, 2021 |
-34.80% |
| Jun 30, 2021 |
212.36% |
